Physician Briefing

Hematology & Oncology News

• Sunscreen Ingredient May Be Linked to Risk of Endometriosis
  Benzophenone-type derivatives may be linked to an increased risk of endometriosis, according to a study published in the April 17 issue of Environmental Science & Technology.
• ASCO: Oncologists Better ID Long-Term Effects of Chemo
  Most oncologists can identify the main late or long-term effects of chemotherapy drugs, but primary care physicians are less likely to be able to do so, according to a study released May 16 in advance of presentation at the annual meeting of the American Society of Clinical Oncology, held from June 1 to 5 in Chicago.
• Adjuvant Radiochemotherapy Has Lasting Benefit in Gastric Cancer
  Ten-year data from the Southwestern Oncology Group-directed Intergroup Study 0116 confirm the benefits of adjuvant radiochemotherapy after gastric cancer resection in terms of overall survival (OS) and relapse-free survival (RFS), according to research published online May 14 in the Journal of Clinical Oncology.
• ASCO: Crizotinib Tolerated, Active in Pediatric Patients
  For pediatric patients with tumors that have genetic aberrations in the anaplastic lymphoma kinase gene, crizotinib is well tolerated and has antitumor activity, according to a study released May 16 in advance of presentation at the annual meeting of the American Society of Clinical Oncology, held from June 1 to 5 in Chicago.
• STAT3 Mutations ID'd in Rare Lymphoproliferative Disorder
  Approximately 40 percent of patients with T-cell large granular lymphocytic leukemia have mutations in the Src homology 2 dimerization and activation domain of the signal transducer and activator of the transcription 3 (STAT3) gene, according to a study published in the May 17 issue of the New England Journal of Medicine.
• Bisphosphonates Cut Skeletal Morbidity in Multiple Myeloma
  For patients with multiple myeloma, bisphosphonate treatment is associated with reduced pathological vertebral fractures, skeletal related events, and pain, but bisphosphonates do not appear to improve overall survival, with the exception of zoledronate, which has been found to be superior to placebo and etidronate for improving overall survival, according to a review and meta-analysis published online May 16 in the The Cochrane Library.

More Hematology & Oncology News

Hematology & Oncology Conference Highlights

• American Association for Cancer Research, March 31-April 4, 2012
• American Academy of Dermatology, March 16-20, 2012
• EBCC: Long-Running Screening Program Cuts Breast CA Deaths
  Results of a mammography screening program, ongoing since 1990 in the Netherlands, has shown that screening coincides with fewer breast cancer deaths, limited harms, and reasonable costs, according to a study presented at the annual European Breast Cancer Conference, held from March 21 to 24 in Vienna.
• ASCO Genitourinary Cancers Symposium, Feb. 2-4, 2012
• ASCO Gastrointestinal Cancers Symposium, Jan. 19-21, 2012

More Hematology & Oncology Conference Highlights

Monthly Briefings

• April 2012 Briefing - Hematology & Oncology

More Monthly Briefings